港股異動丨石藥集團逆勢大漲超12%,正磋商3項潛在授權及合作
石藥集團(1093.HK)逆勢走強,盤初一度大漲超12%,報8.56港元,股價創2023年2月以來新高,截至目前成交額放大至逾20億港元。消息面上,公司公佈,集團目前正與若幹獨立第三方就3項潛在交易進行磋商,涉及集團若幹產品(包括表皮生長因子受體抗體藥物偶聯物(EGFR-ADC)及由集團技術平臺開發的其他藥品)在開發、生產及商業化方面的授權及合作。集團表示,每項潛在交易項下,可能應付予集團的潛在首付款、潛在開發里程碑付款及潛在商業化里程碑付款,合計可能達到約50億美元。3項潛在交易中的其中一項目前已處於後期階段,預計將於6月完成。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.